Фармакотерапия расстройств аутистического спектра у детей: опыт зарубежных психофармакологов

Полный текст:
Читать

Рекомендуемое оформление библиографической ссылки:

Бородина Л.Г. Фармакотерапия расстройств аутистического спектра у детей: опыт зарубежных психофармакологов // Российский психиатрический журнал. 2013. №1. С. 60-70.

Аннотация

В настоящем обзоре представлены последние зарубежные данные по фармакотерапии расстройств аутистического спектра (РАС). Приведены различные показатели эффективности как традиционных групп психотропных препаратов, так и смелых попыток использования других лекарственных групп (гормоны, иммуномодулирующие средства, ингибиторы холинэстеразы) и отдельных медикаментов с недавно обнаруженными антиаутистическими свойствами (ципрогептадин, фаготидин и др.). В начале каждого раздела дается краткая теоретическая справка по группе препаратов и ее связи с клиникой или нейрофизиологией РАС. Особо обсуждается вопрос о возможности воздействия лекарств на основную (ядерную) аутистическую симптоматику. Приводятся данные зарубежных обзоров с градациями препаратов по эффективности, методической правильности и возможности анализа проведенных исследований и перспективности будущих направлений научного поиска.

Ключевые слова детский возраст; аутизм; аутистический спектр; фармакотерапия

Литература

1. Башина В.М., Симашкова Н.В. Аутизм в детстве // Лечение и реабилитация. - М.: Медицина, 1999. - С. 171-206. 2. Брин И.Л., Дунайкин М.Л., Шейнкман О.Г. Элькар в комплексной терапии нарушений нервно-психического развития детей с последствиями перинатальных поражений мозга // Вопр. соврем. педиатрии. - 2005, Т. 4, № 1. 3. Козловская Г.В., Калинина М.А., Горюнова А.В., и др. Опыт применения рисполепта при лечении раннего детского аутизма и шизофрении у детей // Психиатрия и психофармакотер. - 2000. - Т. 1, № 2. - Прил. 4. Симашкова Н.В. Эффективная фармакотерапия и реабилитация больных с расстройствами аутистического спектра // Неврология и психиатрия. - 2011. - № 3. - С. 14-22. 5. Anagnostou E., Hansen R.L. Medical treatment overview: traditional and novel psychopharmacological and complementary and alternative medications // Curr. Opin. Pediatr. - 2011. - Vol. 23 (6). - P. 621-627. 6. Andari E., Duhamel J.R. Zolla T. et al. Promoting social behavior with oxytocin in high functioning autism spectrum disorder // Proc. Natl Acad. Sci. USA. - 2010. - Vol. 107 (9). - P. 4389- 4394. 7. Anderson L.T., Campbell M., Adams P. et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children // J. Autism Dev. Disord. - 1989. - Vol. 19 (2). - P. 2 2 7- 2 3 9 . 8. Baghdadli A., Gounier V., Aussilloux G. Review of psychopharmacological treatments in adolescents and adults with autistic disorders // Encephale. - 2002. - Vol. 28 (3 Pt 1). - P. 24 8 - 2 5 4. 9. Banaschewski T., Poustka L., Holtmann M. Autism and ADHD across the life span. Differential diagnoses or comordidity? // Nervenarzt. - 2011. - Vol. 82 (5). - P. 573-580. 10. Barnard L., Young A.H., Pearson J. et al. A systematic review of the use of atypical antipsychotics in autism // J. Psychopharmacol. - 2002. - Vol. 16 (1). - P. 93-101. 11. Bradstreet J.J., Smith S., Granpeesheh D. et al. Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders // Med. Hypotheses. - 2007. - Vol. 68 (5). - P. 979-987. 12. Branford D., Bhaumik S., Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviors of people with intellectual disability // J. Intellect. Disabil. Res. - 1998. - Vol. 42 (Pt 40). - P. 301-306. 13. Chabrol H., Bonnet D., Roge B. Psychopharmacology of autism // Encephale. - 1996 May-June. - Vol. 22 (3). - P. 197-203. 14. Chanizadeh A. Atomoxetine for Treating ADHD symptoms in Autism: a Systematic Review // J. Atten. Disord. - 2012. - Apr. 27 (Epub ahead of print). 15. Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study // J. Atten Disord. - 2011. - Vol. 15 (8). - P. 684-689. 16. Chez M.G., Guido-Estrada N. Immune therapy in autism: historical experience and future directions with immunomodulatory therapy // Neurotheraputics. - 2010. - Vol. 7 (3). - P. 2 9 3 - 3 0 1. 17. Coo H., Quellette-Kuntz H., Lloyd J.E. et al. Trends in autism prevalence: diagnostic substitution revisited // J. Autism Dev. Disord. - 2008. - Vol. 38 (6). - P. 1036-1046. 18. DeLong G.R., Ritch C.R., Busch S. Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement // Dev. Med. Child Neurol. - 2002. - Vol. 44 (10). - P. 652-659. 19. Dollfus S., Petit M., Menard J.F. et al. Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function // J. Autism Dev. Disord. - 1992. - Vol. 22 (1). - P. 47-60. 20. Elbe D., Lalani Z. Review of the pharmacotherapy of irritability of autism // J. Can. Acad. Child Adolesc. Psychiatry. - 2012. - Vol. 21 (2). - P. 130-146. 21. Fink H., Taylor M.A., Chaziuddin N. Catatonia in autistic spectrum disorders: a medical treatment algorithm // Int. Rev. Neurobiol. - 2006. - Vol. 72. - P. 233-244. 22. Frye R.E., Huffman L.C., Elliott G.R. Tetrahydrobiopterin as a novel therapeutic intervention for autism // Neurotheraputics. - 2010. - Vol. 7 (3). - P. 241-249. 23. Frye R.E., Sreenivasula S., Adams J.B. Traditional and nontraditional treatments for autism spectrum disorders with seizures: an on-line survey // BMC Pediatr. - 2011. - Vol. 18. - P. 11- 3 7. 24. Garcia-Penas J.J. Antiepileptic drugs in the treatment of autistic regression syndrome // Rev. Neurol. - 2005. - Vol. 40, suppl. 1. - P. s173-s176. 25. Goiness P., Van de Water J. The immune system’s role in the biology of autism // Curr. Opin. Neurol. - 2010. - Vol. 23 (2). - P. 111-117. 26. Gralton E.J., james D.H., Lindsey M.P. Antipsychotic medication, psychiatric diagnosis and children with intellectual disability // J. Intellect. Disabil. Res. - 1998. - Vol. 42 (Pt 1). - P. 4 9 - 5 7. 27. Green J.J., Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics // Neurotheraputics. - 2010. - Vol. 7 (3). - P. 250-257. 28. Guastella A.J., Einfeld S.L., Gray R.M. et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorder // Biol. Psychiatry. - 2010. - Vol. 67 (7). - P. 692-694. 29. Hjiej H., Doyen C., Couprie C., Kaye K. et al. Substitutive and dietic approaches in childhood autistic disorder: interests and limits // Encephale. - 2008. - Vol. 34 (5). - P. 496-503. 30. Hollander E., Chaplin W., Soorya L. et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders // Neuropsychopharmacology. - 2010. - Vol. 35 (4). - P. 990-998. 31. Huffman L.S., Sutcliffe T.L., Tanner I.S. et al. Management of symptoms in children with autism spectrum disorders: a comprehensive review of pharmacologic and complementary - alternative medicine treatments // J. Dev. Behav. Pediatr. - 2011. - Vol. 32 (1). - P. 56-68. 32. James S., Montgomery P., Williams K. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD) // Cochrane Database Syst. Rev. - 2011 Nov. 9; (11): CD 007992. 33. Janusonis S. Origin of the blood hyperserotoninemia of autism // Theor. Biol. Med. Model. - 2008. - Vol. 3 (1). - P. 3 5 5 - 3 6 2 . 34. Jorgensen O.S. Psychopharmacological treatment of psychotic children. A survey // Acta Psychiatr. Scand. - 1979. - Vol. 59 (2). - P. 229-238. 35. Kakooza-Mwesige A., Wachtel L.E., Dhosshe D.M. Catatonia in autism: implications across the life span // Eur. Child Adolesc. Psychiatry. - 2008. - Vol. 17 (6). - P. 327-335. 36. Kaplan G., McCracken J.T. Psychopharmacology of autism spectrum disorders // Pediatr. Clin. North Am. - 2012. - Vol. 59. - P. 17 5 -18 7. 37. King C.R. A novel embryological theory of autism causation involving endogenous biochemicals capable of initiating cellular gene transcription: a possible link between twelve autism risk factors and the autism "epidemic" // Med. Hypotheses. - 2011. - Vol. 76 (5). - P. 653-660. 38. Krishnaswami S., McPheeters M.L., Veenstra-Vanderweele J. A systematic review of secretin for children with autism spectrum disorders // Pediatrics. - 2011. - Vol. 127 (5). - P. e1322-e1325. 39. Leventhal B.L., Cook E.V. Jr, Morford M. et al. Clinical and neurochemical effects of fenfluramine in children with autism // J. Neuropsychiatry Clin. Neurosci. - 1993. - Vol. 5 (3). - P. 307-315. 40. Linday L.A. Oral famotidine: a potential treatment for children with autism // Med. Hypotheses. - 1997. - Vol. 48 (5). - P. 381-386. 41. Linday L.A., Tsiouris J.A., Cohen I.L. et al. Famotidine treatment for children with autistic spectrum disorders: pilot research using single subject research design // J. Neurol. Transm. - 2001. - Vol. 108 (5). - P. 593-611. 42. Luby J., Mrakotsky C., Stalets M.M. et al. Risperidone in preschool children with autism spectrum disorders: an investigation of safety and efficacy // J. Child Adolesc. Psychopharmacol. - 2006. - Vol. 16 (5). - P. 575-587. 43. Marrosu F., Marrozu G., Rachel M.G. et al. Paradoxical reactions elicited by diazepam in children with classic autism // Funct. Neurol. - 1987 Jul-Sep. - Vol. 2(3). - P. 355-361. 44. Matarazzo E.B. Treatment of late onset autism as a consequence of probable autoimmune processes related to chronic bacterial infection // World J. Biol. Psychiatry. - 2002. - Vol. 3 (3). - P. 162-166. 45. McCracken J.T. Safety issues with drug therapies for autism spectrum disorder // J. Clin. Psychiatry. - 2005. - Vol. 66, suppl. 10. - P. 32-37. 46. McDougle C.L., Brodkin E.S., Naylor S.T. et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation // J. Clin. Psychopharmacol. - 1998. - Vol. 18 (1). - P. 62-66. 47. McDougle C.L., Kresch L.E., Posey D.G. Repetetive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors // J. Autism Dev. Disord. - 2000 Oct. - Vol. 30 (5). - P. 427-435. 48. McDougle C.L., Kem D.L., Posey D.G. Case series: use of ziprasidone for maladaptive symptoms in youth with autism // J. Am. Acad. Child Adolesc. Psychiatry. - 2002. - Vol. 41 (8). - P. 921-927. 49. McKinney C., Renk K. Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations // Clin. Psychol. Rev. - 2011. - Vol. 31 (3). - P. 465-471. 50. McPheeters M.L., Warren Z., Sathe N. A systematic review of medical treatments for children with autism spectrum disorders // Pediatrics. - 2011. - Vol. 127, N 5. - P. e1312-e1321. 51. Millward C., Ferriter M., Calver S. et al. Gluten- and casein-free diet for autistic spectrum disorders // Cochrane Database Syst. Rev. - 2008. - Vol. 16 (2): CD 003498. 52. Ming X., Julu P.O., Brimacombe M. et al. Reduced cardiac parasympathetic activity in children with autism // Brain Dev. - 2005. - Vol. 5. - P. 486-493. 53. Modi M.E., Young L.J. The oxytocin system in drug discovery for autism: animal models and novel therapeutic strategies // Horm. Behav. - 2012. - Vol. 61 (3). - P. 340-350. 54. Moscal J.R., Burqdorf J. A novel NMDA receptor glycine-syte partial agonist GLYX-13 has therapeutic potential for the treatment of autism // Neurosci. Biobehav. Rev. - 2011. - Vol. 35 (9). - P. 19 8 2 -19 8 8 . 55. Newcomer J.W. Second-generation (atypical) antipsycotics and metabolic effects: a comprehensive literature review // CNS Drugs. - 2005. - Vol. 19, suppl. 1. - P. 1-93. 56. Niederhofer H., Staffen W., Mair A. Galantamine might be effective in treating autistic disorder // BMJ. - 2002. - Vol. 325 (7377). - P. 1422. 57. Posey D.J., Walsh K.H., Wilson G.A. et al. Risperidone in the treatment of two very young children with autism // J. Child Adolesc. Psychopharmacol. - 1999. - Vol. 9 (4). - P. 273-276. 58. Posey D.J., McDougle C.J. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders // Harv. Pev. Psychiatry. - 2000. - Vol. 8 (2). - P. 45-63. 59. Posey D.J., Puntney J.I., Sasher T.M. et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases // J. Child Adolesc. Psychopharmacol. - 2004. - Vol. 14 (2). - P. 2 3 3 - 241. 60. Posey D.J., Erickson C.A., McDougle C.J. Developing drugs for core social and communication impairment in autism // Child Adolesc. Psychiatr Clin. N. Am. - 2008. - Vol. 17 (4). - P. 7 8 7. 61. Poustka L., Banaschewski T., Poustka F. Psychopharmacology of autism spectrum disorders // Nervenarzt. - 2011. - Vol. 82 (5). - P. 582-589. 62. Rajapakse T., Pringsheim T. Pharmacotheraputics of Tourette syndrome and stereotypes in autism // Semin. Pediatr. Neurol. - 2010. - Vol. 17 (4). - P. 254-260. 63. Realmuto G.M., August G.J., Garfinkel B.D. Clinical effect of buspirone in autistic children // J. Clin. Psychopharmacol. - 1989. - Vol. 9 (2). - P. 122-125. 64. Robb A.S. Managing irritability and aggression in autism spectrum disorders in children and adolescents // Dev. Disabil. Res. Rev. - 2010. - Vol. 16 (3). - P. 258-264. 65. Rossignol D.A. Novel and emerging treatments for autism spectrum disorder: a systematic review // Ann. Clin. Psychiatry. - 2009. - Vol. 21 (4). - P. 213-236. 66. Rossignol D.A., Frye R.E. Melatonin in autism spectrum disorders: a systematic review and meta-analysis // Dev. Med. Child Neurol. - 2011. - Vol. 53 (9). - P. 783-792. 67. Rossignol D.A., Frye R.E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis // Mol. Psychiatry. - 2012. - Vol. 17 (3). - P. 290-314. 68. Rothenberger A. Psychopharmacological treatment of self-injurious behavior in individuals with autism // Acta Paedopsychiatr. - 1993. - Vol. 56 (2). - P. 99-103. 69. Rugino T.A., Samsock T.C. Levetiracetam in autistic children: an open-label study // J. Dev. Behav. Pediatr. - 2002. - Vol. 23 (4). - P. 22-30. 70. Shattock P., Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention // Expert Opin. Theor. Targets. - 2002. - Vol. 6 (2). - P. 175-183. 71. Sloman L. Use of medication in pervasive developmental disorders // Psychiatr. Clin. North Am. - 1991. - Vol. 14 (1). - P. 16 5 -18 2 . 72. Stachnik J.M., Nunn-Thompson C. Use of atypical antipsychotics in the treatment of autistic disorder // Ann. Pharmacother. - 2007. - Vol. 41 (4). - P. 626-634. 73. Wei H., Dobkin C., Sheikh F.M. et al. the therapeutic effect of memantine through the stimulanion of synapse formation and dendritic spine maturation in autism and fragile X syndrome // PLoS One. - 2012. - Vol. 7 (5). - P. e 36981. 74. White S.W., Oswald D., Ollendick T. et al. Anxiety in children and adolescents with autism spectrum disorders // Clin. Psychol. Rev. - 2009. - Vol. 29 (3). - P. 216-229. 75. Zuddas A., Di Martino A., Muglia P. et al. Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation // J. Child Adolesc. Psychopharmacol. - 2000. - Vol. 10 (2). - P. 79-90.

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM